Phage Display in Cancer Diagnosis and Screening

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Bacterial Viruses".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 741

Special Issue Editor


E-Mail Website
Guest Editor
College of Veterinary Medicine, Auburn University, Auburn, AL, USA
Interests: phage display and phage nanobiotechnology; targeted drug and gene delivery; cancer nanomedicines; diagnosis of infectious diseases and cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Early cancer diagnosis is highly beneficial for the survival of cancer patients. Therefore, there is an urgent need for screening tools for the identification of early signs of cancer pathologies before symptoms appear. Despite recent progress in early diagnosis using liquid biopsy technologies, the early blood-based detection of breast, lung, colorectal, and other cancers is still a challenge. In this respect, the “Holy Grail” for cancer researchers and bioengineers for decades has been the use of molecular sensing probes, which would allow for the screening, diagnosis, prognosis, and monitoring of cancer diseases by their highly specific interactions with cancer cellular antigens and overexpressed blood biomarkers. To date, most analytical platforms for the detection of cancer biomarkers use monoclonal antibodies (mAb) as targeting and sensing probes. However, because of their high cost, background binding, and technological and storage hardships, the application of mAb as an analytical standard is limited. This Special Issue aims to demonstrate the power of phage display as a universal tool for directed molecular evolution in cancer research. We call for manuscripts that explore the fundamental principles of phage display and molecular evolution in novel ways in the development of diagnostics for cancer diseases.

Prof. Dr. Valery A. Petrenko
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • phage display
  • cancer
  • diagnosis
  • screening
  • prognosis and monitoring

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 2323 KB  
Article
Discovery of Landscape Phage Probes Against Cellular Communication Network Factor 1 (CCN1/Cyr61)
by James W. Gillespie and Valery A. Petrenko
Viruses 2025, 17(9), 1273; https://doi.org/10.3390/v17091273 - 19 Sep 2025
Viewed by 202
Abstract
Detection of cancer biomarkers at the earliest stages of disease progression is commonly assumed to extend the overall quality of life for cancer patients as the result of earlier clinical management of the disease. Therefore, there is an urgent need for the development [...] Read more.
Detection of cancer biomarkers at the earliest stages of disease progression is commonly assumed to extend the overall quality of life for cancer patients as the result of earlier clinical management of the disease. Therefore, there is an urgent need for the development of standardized, sensitive, robust, and commonly available screening and diagnostic tools for detecting the earliest signals of neoplastic pathology progression. Recently, a new paradigm of cancer control, known as multi-cancer detection (MCD), evolved, which measures the composition of cancer-related molecular analytes in the patient’s fluids using minimally invasive techniques. In this respect, the “Holy Grail” of cancer researchers and bioengineers for decades has been composing a repertoire or molecular sensing probes that would allow for the diagnosis, prognosis, and monitoring of cancer diseases via their interaction with cell-secreted and cell-associated cancer antigens and biomarkers. Therefore, the current trend in screening and detection of cancer-related pathologies is the development of portable biosensors for mobile laboratories and individual use. Phage display, since its conception by George Smith 40 years ago, has emerged as a premier tool for molecular evolution in molecular biology with widespread applications including identification and screening of cancer biomarkers, such as Circulating Cellular Communication Network Factor 1 (CCN1), an extracellular matrix-associated signaling protein responsible for a variety of cellular functions and has been shown to be overexpressed as part of the response to various pathologies including cancer. We hypothesize that CCN1 protein can be used as a soluble marker for the early detection of breast cancer in a multi-cancer detection (MCD) platform. However, validated probes have not been identified to date. Here, we screened the multi-billion clone landscape phage display library for phages interacting specifically with immobilized CCN1 protein. Through our study, we discovered a panel of 26 different phage-fused peptides interacting selectively with CCN1 protein that can serve for development of a novel phage-based diagnostic platform to monitor changes in CCN1 serum concentration by liquid biopsy. Full article
(This article belongs to the Special Issue Phage Display in Cancer Diagnosis and Screening)
Show Figures

Figure 1

Back to TopTop